In-house platelet transfusion from a corresponding HLA donor to an anti-HLA-antibody-positive patient

In-house platelet transfusion from a corresponding HLA donor to an anti-HLA-antibody-positive patient - In-house platelet transfusion

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000049715

Enrollment

Registered

2022-12-08

Start date

2022-12-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematologic disorders

Interventions

in-house platelet transfusion

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patient with hematopoietic diseases who are refractory to chemotherapy and for whom allogeneic hematopoietic stem cell transplantation is the only curative option

Exclusion criteria

Exclusion criteria: Case that sufficient stem cells cannot be harvested from the donor

Design outcomes

Primary

Measure	Time frame
Titer of donor-specific antibodies	—

Secondary

Measure	Time frame
engraftment	—

Countries

Japan

Contacts

Public ContactAyako Arai

St. Marianna University School of Medicine Division of Hematology & Oncology, Department of Internal Medicine

ara.hema@marianna-u.ac.jp044-977-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026